Cartesian Therapeutics Says US FDA Agrees to Phase 3 Myasthenia Gravis Trial Design

MT Newswires Live
27 Jan

Cartesian Therapeutics (RNAC) said Monday the US Food and Drug Administration has agreed to the design of its phase 3 AURORA trial for Descartes-08, its mRNA cell therapy for myasthenia gravis, a chronic autoimmune disorder that causes muscle weakness.

The company said the randomized trial, expected to begin in H1, will compare Descartes-08 to a placebo in about 100 participants with acetylcholine receptor autoantibody-positive myasthenia gravis.

The primary endpoint will measure the percentage of patients with a three-point or greater improvement in myasthenia gravis activities of daily living scores after four months, Cartesian added.

Shares of the company were up 2.9% in recent Monday trading.

Price: 19.76, Change: +0.56, Percent Change: +2.89

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10